Carisma Therapeutics, Inc.
CARM
$0.235
$0.00924.07%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 9.77% | -14.83% | -11.55% | 158.34% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 9.77% | -14.83% | -11.55% | 158.34% |
| Cost of Revenue | -84.16% | -47.57% | -19.76% | -42.07% | -17.34% |
| Gross Profit | 60.33% | 61.41% | 21.16% | 49.50% | 59.15% |
| SG&A Expenses | -39.68% | -28.25% | -46.34% | -21.40% | -7.44% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -72.31% | -42.97% | -27.04% | -36.84% | -14.92% |
| Operating Income | 50.49% | 52.16% | 29.38% | 41.17% | 44.34% |
| Income Before Tax | 12.44% | 51.18% | 16.64% | 40.65% | 43.59% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 12.44% | 51.18% | 15.86% | 40.65% | 43.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 12.44% | 51.18% | 15.86% | 40.65% | 43.84% |
| EBIT | 50.49% | 52.16% | 29.38% | 41.17% | 44.34% |
| EBITDA | 49.38% | 51.32% | 30.11% | 42.69% | 43.63% |
| EPS Basic | 12.95% | 52.16% | 18.60% | 42.52% | 45.57% |
| Normalized Basic EPS | 52.71% | 52.16% | 28.51% | 42.50% | 45.35% |
| EPS Diluted | 12.95% | 52.16% | 18.60% | 42.52% | 45.57% |
| Normalized Diluted EPS | 52.71% | 52.16% | 28.51% | 42.50% | 45.35% |
| Average Basic Shares Outstanding | 0.59% | 2.03% | 3.37% | 3.23% | 3.19% |
| Average Diluted Shares Outstanding | 0.59% | 2.03% | 3.37% | 3.23% | 3.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |